Exhibit 99.1
CytoDyn Announces Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs
VANCOUVER, Washington, November 17, 2026 – CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including colorectal cancer (CRC) and triple-negative breast cancer (TNBC), today announced Lauren Wilcoxen, Ph.D., as its new Chief Operating Officer and Head of Regulatory Affairs, effective November 20, 2026.
Dr. Wilcoxen brings extensive experience in regulatory affairs, clinical development and biotechnology operations, including a track record of advancing oncology programs through key regulatory milestones. Most recently, she served as Senior Vice President of Regulatory Affairs at Xilio Therapeutics, Inc. (NASDAQ: XLO), a publicly traded clinical-stage biotechnology company. From May 2022 to October 2025, Dr. Wilcoxen helped lead a team that secured FDA approval of a novel checkpoint inhibitor for skin cancer while serving as Senior Vice President, Product Development and Regulatory Affairs of Checkpoint Therapeutics, Inc. (formerly, NASDAQ: CKPT), a publicly traded clinical-stage biotechnology company, until its acquisition by Sun Pharmaceutical Industries, Inc. in 2025. Over the past several years, she has also advised various public and private biotechnology and pharmaceutical companies on regulatory strategy, clinical development and operational execution, with a focus on navigating complex oncology development programs and coordinating cross-functional teams.
“Lauren's appointment comes at an important time for CytoDyn as we continue to advance our oncology development strategy and build on emerging findings from our CLOVER study,” said Robert E. Hoffman, Chief Executive Officer of CytoDyn. “Her extensive regulatory expertise, recent success working with the FDA's Division of Oncology, and firsthand knowledge of our clinical programs make her exceptionally well suited to help guide CLOVER through the completion of Phase 2 and shape our regulatory strategy for the next stages of leronlimab's development. We are pleased to welcome her to our executive leadership team.”
Dr. Wilcoxen has served as a consultant to CytoDyn over the past year, advising on key clinical decisions and gaining firsthand knowledge of the Company's clinical programs, including its Phase 2 CLOVER study evaluating leronlimab in metastatic colorectal cancer.
“Having worked closely with CytoDyn over the past year, I have developed a strong understanding of leronlimab's scientific rationale, the CLOVER study, and the opportunities ahead for the Company's oncology programs,” said Dr. Wilcoxen. “I am encouraged by the emerging clinical findings and look forward to working with the team to translate these insights into a clear, rigorous regulatory and clinical development strategy. Our priority will be to work closely with the FDA to define a clear regulatory strategy that supports leronlimab’s continued clinical development.”